Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | HTR3A | P46098 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10600837 | 0.79 | ESR1 (0.63) | ESR1ESR2TAAR1HTR3ATSHR | |
| SCHEMBL13461667 | 0.79 | ESR1 (0.63) | ESR1ESR2ALOX15TDP1CYP2C19 | |
| SCHEMBL6719945 | 0.77 | ADRB1 (0.43) | ESR1ESR2TAAR1TSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL10772227 | 0.76 | LMNA (0.42) | ESR1ESR2TAAR1TSHRNFKB1 | |
| SCHEMBL11891939 | 0.75 | ESR1 (0.58) | ESR1ESR2CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL243609 | 0.70 | TAAR1 (0.62) | ESR1ESR2TAAR1HTR3ATSHR | |
| Octopamine SCHEMBL1650462 | 0.69 | TAAR1 (1.00) | ESR1TAAR1HTR3ATSHRNFKB1 | |
| Bromide SCHEMBL28653897 | 0.69 | TAAR1 (0.60) | ESR1ESR2TAAR1HTR3ATSHR | |
| Octopamine SCHEMBL22605 | 0.69 | TAAR1 (1.00) | ESR1TAAR1HTR3ATSHRNFKB1 | |
| Octopamine SCHEMBL3489184 | 0.69 | TAAR1 (1.00) | ESR1TAAR1HTR3ATSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| EP-0250264-A1 | Irreversible dopamine-Beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1987-12-23 | — | — | EP | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | disclosed |
| US-20040053355-A1 | Modular approach to on-line synthesis, drug discovery and biochemical transformations using immobilized enzyme reactors | MCGILL UNIVERSITY (CA) | 2004-03-18 | — | — | US | disclosed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | disclosed |
| EP-1290133-A1 | MODULAR APPROACH TO ON-LINE SYNTHESIS, DRUG DISCOVERY AND BIOCHEMICAL TRANSFORMATIONS USING IMMOBILIZED ENZYME REACTORS | McGill University (CA) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001090298-A1 | MODULAR APPROACH TO ON-LINE SYNTHESIS, DRUG DISCOVERY AND BIOCHEMICAL TRANSFORMATIONS USING IMMOBILIZED ENZYME REACTORS | MCGILL UNIVERSITY (CA) | 2001-11-29 | — | — | WO | disclosed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | disclosed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | ESR1 4214/4885ESR2 4555/4885TAAR1 790/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | ESR1 4384/4885ESR2 4614/4885TAAR1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.